R. JOHN FLETCHER - Corporate Board Profile

KORU Medical Systems, Inc.

Filing Date	Source Excerpt
2020-03-06	Mr. Fletcher brings more than 35 years of healthcare and medical device experience to KORU. He currently serves as CEO and Managing Director of Fletcher Spaght Inc., a strategy consulting and venture capital firm which he founded in 1983. Mr. Fletcher joined the Board of Directors of publicly-traded medical device company Spectranetics Corporation in 2002 and served as Chairman of the Board from 2010-2017. Mr. Fletcher was named 2018 Director of the Year by The National Association of Corporate Directors (NACD) for his work at Spectranetics. Mr. Fletcher currently serves on the Board of Directors of Axcelis Corporation, MRI Interventions, Inc and is Chairman of Metabolon, Inc. He is Chairman Emeritus of the Corporate Collaboration Council at the Thayer School of Engineering/Tuck School of Business at Dartmouth College and serves on the Board of Advisors of Beth Israel Deaconess Medical Center and the Whitehead Institute at MIT. Mr. Fletcher received his MBA from Southern Illinois University and a BBA in Marketing from George Washington University. The Audit Committee is currently comprised of Messrs. Anderson (chair), Allen and Fletcher and Ms. Frommer. The Nomination and Governance Committee currently consists of Messrs. Manko (chair), Allen and Fletcher. The 2019 fiscal year director compensation table shows R. John Fletcher with total compensation of $45,058.
2021-04-05	Mr. Fletcher brings more than 35 years of healthcare and medical device experience to KORU. He currently serves as CEO and Managing Director of Fletcher Spaght Inc., a strategy consulting and venture capital firm which he founded in 1983. Mr. Fletcher joined the Board of Directors of publicly-traded medical device company Spectranetics Corporation in 2002 and served as Chairman of the Board from 2010-2017. Mr. Fletcher was named 2018 Director of the Year by The National Association of Corporate Directors (NACD) for his work at Spectranetics. Mr. Fletcher currently serves on the Board of Directors of Axcelis Corporation, Chairman of ClearPoint Neuro (formerly MRI Interventions) and is Chairman of Metabolon, Inc. He is Chairman Emeritus of the Corporate Collaboration Council at the Thayer School of Engineering/Tuck School of Business at Dartmouth College and serves on the Board of Advisors of Beth Israel Deaconess Medical Center and the Whitehead Institute at MIT. Mr. Fletcher received his MBA from Southern Illinois University and a BBA in Marketing from George Washington University. The Audit Committee is currently comprised of Messrs. Anderson (chair), Allen and Fletcher and Ms. Frommer. Each member of this committee is “independent” within the meaning of applicable SEC rules and standards of the Nasdaq Stock Market LLC (the “Nasdaq”). The Board of Directors has designated Mr. Anderson as the audit committee financial expert, as currently defined under the SEC rules. The Nominating and Governance Committee currently consists of Messrs. Manko (chair), Allen and Fletcher. Each member of this committee is “independent” within the meaning of applicable SEC rules and the standards of the Nasdaq. The Audit Committee held six meetings including two special meetings in connection with meetings of the full Board during the fiscal year ended December 31, 2020. The Nominating and Governance Committee held five meetings including one special meeting during the fiscal year ended December 31, 2020. 2020 FISCAL YEAR DIRECTOR COMPENSATION TABLE: R. John Fletcher Fees Earned or Paid in Cash ($) 25,000 Stock Awards ($) 75,000 All Other Compensation ($) — Total ($) 100,000.
2022-03-18	The following table sets forth the name, age and positions of each Director Nominee: R. John Fletcher 76 Chairman of the Board (since September 2019) Director (since May 2019). The Audit Committee is currently comprised of Messrs. Anderson (chair), Allen and Beck and Dr. French. The Nominating and Governance Committee currently consists of Messrs. Manko (chair), Allen and Fletcher. The 2021 Fiscal Year Director Compensation Table shows R. John Fletcher total compensation of $102,335.
2023-03-29	R. John Fletcher Chairman of the BoardManaging Partner Emeritus, Fletcher Spaght Inc. Age 77 Committee Membership: AC (Member), CC (Member) Annual Compensation: $140,000
2024-03-28	R. John Fletcher Chairman of the Board Nominating and Governance Committee Chair Cash Retainer $50,000 Common Stock Award $90,000 Total $140,000 Committee Membership: Audit Committee Member Compensation Committee Member Nominating and Governance Committee Chair
2025-04-04	Mr. Fletcher brings more than 40 years of healthcare and medical device experience to KORU. He currently serves as Managing Partner Emeritus of Fletcher Spaght Inc., a healthcare-focused strategy consulting firm which he founded in 1983, and Managing Partner of Fletcher Spaght Ventures, a venture capital firm which he founded in 2001. Mr. Fletcher joined the Board of Directors of publicly-traded medical device company Spectranetics Corporation in 2002 and served as Chairman of the Board from 2010-2017. Mr. Fletcher was named 2018 Director of the Year by The National Association of Corporate Directors (NACD) for his work at Spectranetics and Axcelis. Mr. Fletcher currently serves as Chairman of ClearPoint Neuro (formerly MRI Interventions) and is Chairman of Metabolon, Inc., as well as, Chairman of the Board of Optinose, Inc. He is Chairman Emeritus of the Corporate Collaboration Council at the Thayer School of Engineering/Tuck School of Business at Dartmouth College and serves on the Board of Advisors of Beth Israel Deaconess Medical Center and the Whitehead Institute at MIT. Mr. Fletcher received his MBA from Southern Illinois University, a BBA in Marketing from George Washington University and an MS in international finance from Central Michigan University. Mr. Fletcher was also an instructor and PhD candidate at the Wharton School, University of Pennsylvania.